Gedea Biotech AB

Gedea Biotech AB is a Swedish biotechnology company based in Lund, founded in 2015. The company specializes in innovative, antibiotic-free treatments for women's health, particularly targeting vaginal infections such as bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC). Gedea Biotech aims to address global women's health challenges, with a focus on reducing unnecessary antibiotic use in response to concerns about antibiotic resistance.

The company's lead product, pHyph, is a vaginal tablet designed to restore vaginal pH, dissolve biofilm, and promote a healthy vaginal microbiome. Clinical studies indicate that pHyph provides rapid symptom relief, with a high percentage of users experiencing improvement within a week. Gedea Biotech is actively pursuing CE-marking and commercialization, supported by significant funding, including a €2.5 million EIC Accelerator grant. The company is committed to advancing women's health solutions and is involved in ongoing clinical trials to further validate its products.